Latest news with #EuropeanAssociationofUrologyCongress
Yahoo
25-03-2025
- Health
- Yahoo
Elypta's urine test identifies 90% of recurrent kidney cancer cases
Swedish cancer diagnostic company Elypta's urine test has been able to accurately identify 90% of patients with recurrent kidney cancer. The business announced the intermediary results from its prospective multi-centre trial designed to determine if urine-collected glycosaminoglycans (GAGomes) can be used for the early detection of cancer recurrence. Specifically, following curative surgery in patients with high or intermediate risk of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. Elypta announced the early results as part of the 2025 European Association of Urology Congress, taking place in Madrid, Spain. The trial was co-funded by the European Union's Horizon 2020 research and innovation programme and took place at 29 international locations. The trial featured an adaptive design with primary endpoint analysis carried out after 30 events or recurrences had been reached. The company says the results underline the ability of clinicians to pivot away from the use of radiological examination for post-treatment patients, instead pushing for the use of patients' submitted urine samples as routine observation. Now, Elypta claims that the study's second patient cohort is nearing final recruitment, with validation results expected later this year. Elypta chief medical officer Volker Liebenberg said: 'A urine test can offer a less invasive and more comfortable alternative for post-operative monitoring, potentially transforming kidney cancer follow-up care.' Commenting on results from the AUR87A trial, Elypta CEO Karl Bergman said: 'These findings show the potentially transformative impact a urine-based test may have in the surveillance of recurrent disease for kidney cancer patients.' Elsewhere in the field of cancer diagnostics, Proscia has secured $50m to advance its AI-driven digital pathology platform designed to allow clinicians to interpret whole slide images. "Elypta's urine test identifies 90% of recurrent kidney cancer cases" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
24-03-2025
- Health
- Yahoo
Erectile function improved in men given prostate cancer check
A technique to preserve nerves during prostate cancer surgery almost doubles the proportion of men who keep erectile function, according to a new study. Compared to standard surgery, researchers said the new method could dramatically improve men's quality of life. Experts from University College London (UCL) and University College London Hospitals NHS Foundation Trust (UCLH) led the study, which will be presented at the European Association of Urology Congress in Madrid and published in the Lancet Oncology journal. It evaluated a method called NeuroSafe to preserve the nerves running through the prostate's outer layers, which are thought to be responsible for producing erections. During cancer surgery, the prostate is removed while the nerves are left intact. The prostate is then examined closely by a pathologist while the patient is still in surgery. The pathologist slices the area near to the nerves in 5mm strips, which are then quickly frozen and stained so they can be looked at through a microscope. The samples are analysed to see if any cancer cells are present. If there are none, the surgeons know that they can leave the patient's nerves intact in their body. If cancer is present, they know nerves will have to be removed. NeuroSafe happens in real-time during the operation, making it vastly different to traditional methods, where tissue samples are sent off and it takes two or three weeks to get results back. Professor Greg Shaw, trial lead from UCL and consultant urologist at UCLH, said some younger men in particular worry about surgery causing impotence and incontinence. He said: 'Our results show that, by using NeuroSafe, nearly twice as many men don't have to face potentially life-changing loss of erectile function after prostate surgery. 'It is an involved procedure that requires expertise, but it isn't expensive, particularly given the benefits it offers for patients, and most importantly doesn't jeopardise cancer control. 'NeuroSafe wouldn't be appropriate for all patients, as many can safely have nerve-sparing surgery using standard robotic techniques. 'But for younger patients and those who wouldn't normally be seen as eligible for nerve-sparing surgery, it offers them a greater chance to hold onto their quality of life.' Prof Shaw said the technology is not new but 'whereas before there wasn't evidence to support this approach, now we have the data to show that, actually, your outcomes are better'. Some 30% of the men in the study were from Afro Caribbean backgrounds. They tend to be diagnosed at a younger age with prostate cancer than white counterparts. The trial ran at five UK hospitals and included 344 men diagnosed with prostate cancer. Half were randomised to receive NeuroSafe during their operation and half had standard surgery. Twelve months after surgery, 39% of men in the NeuroSafe group had no or mild erectile dysfunction. In those men who had standard surgery, this was 23%. A year after their operation, only 38% of those who had surgery using NeuroSafe had severe erectile dysfunction, compared to 56% of men who had standard surgery. NeuroSafe patients who recovered their urinary control also did so faster than patients who underwent standard surgery. Prof Shaw now hopes more men will be able to access NeuroSafe on the NHS as long as the right pathology support is available. He told the PA news agency: 'Whether it can be rolled out or not depends on, I think, finding a good test that gives a similar result (to the pathologist's work) that's perhaps more easily performed, because it's quite complex. 'But the impetus for the community is you're doubling the chances of a man being potent afterwards. And that's compelling.' Dr Ricardo Almeida-Magana, from UCL, said: 'NeuroSafe offers surgeons a real-time evaluation of the safety of the procedure. 'In standard robotic surgery, surgeons determine whether to choose nerve sparing based on MRI scans, on digital rectal examinations and on biopsy results prior to surgery. 'But whereas those methods can provide guidance, NeuroSafe provides certainty. 'And that opens up the option of nerve-sparing surgery for many more men, without compromising on the chances of controlling the cancer.'
The Independent
24-03-2025
- Health
- The Independent
Breakthrough in prostate cancer treatment offers hope for erectile function
A groundbreaking surgical technique could revolutionise prostate cancer treatment by significantly improving erectile function preservation. A new study, led by experts from University College London (UCL) and University College London Hospitals NHS Foundation Trust (UCLH), has found that the NeuroSafe method nearly doubles the proportion of men who maintain erectile function after prostate cancer surgery. The NeuroSafe technique focuses on preserving the delicate nerves that run through the outer layers of the prostate, believed to be crucial for erectile function. These nerves are often damaged or removed during traditional prostate cancer surgery, leading to erectile dysfunction. This new method, however, offers a more precise approach, minimising nerve damage and maximising the chances of preserving sexual function. The study's findings, presented at the European Association of Urology Congress in Madrid and published in the Lancet Oncology, demonstrate a significant improvement in patient outcomes compared to standard surgical procedures. Researchers believe this innovative technique could dramatically enhance men's quality of life following prostate cancer treatment. During cancer surgery, the prostate is removed while the nerves are left intact. The prostate is then examined closely by a pathologist while the patient is still in surgery. The pathologist slices the area near to the nerves in 5mm strips, which are then quickly frozen and stained so they can be looked at through a microscope. The samples are analysed to see if any cancer cells are present. If there are none, the surgeons know that they can leave the patient's nerves intact in their body. If cancer is present, they know nerves will have to be removed. NeuroSafe happens in real-time during the operation, making it vastly different to traditional methods, where tissue samples are sent off and it takes two or three weeks to get results back. Professor Greg Shaw, trial lead from UCL and consultant urologist at UCLH, said some younger men in particular worry about surgery causing impotence and incontinence. He said: 'Our results show that, by using NeuroSafe, nearly twice as many men don't have to face potentially life-changing loss of erectile function after prostate surgery. 'It is an involved procedure that requires expertise, but it isn't expensive, particularly given the benefits it offers for patients, and most importantly doesn't jeopardise cancer control. 'NeuroSafe wouldn't be appropriate for all patients, as many can safely have nerve-sparing surgery using standard robotic techniques. 'But for younger patients and those who wouldn't normally be seen as eligible for nerve-sparing surgery, it offers them a greater chance to hold onto their quality of life.' Prof Shaw said the technology is not new but 'whereas before there wasn't evidence to support this approach, now we have the data to show that, actually, your outcomes are better'. Some 30 per cent of the men in the study were from Afro Caribbean backgrounds. They tend to be diagnosed at a younger age with prostate cancer than white counterparts. The trial ran at five UK hospitals and included 344 men diagnosed with prostate cancer. Half were randomised to receive NeuroSafe during their operation and half had standard surgery. Twelve months after surgery, 39 per cent of men in the NeuroSafe group had no or mild erectile dysfunction. In those men who had standard surgery, this was 23 per cent. A year after their operation, only 38 per cent of those who had surgery using NeuroSafe had severe erectile dysfunction, compared to 56 per cent of men who had standard surgery. NeuroSafe patients who recovered their urinary control also did so faster than patients who underwent standard surgery. Prof Shaw now hopes more men will be able to access NeuroSafe on the NHS as long as the right pathology support is available. He said: 'Whether it can be rolled out or not depends on, I think, finding a good test that gives a similar result (to the pathologist's work) that's perhaps more easily performed, because it's quite complex. 'But the impetus for the community is you're doubling the chances of a man being potent afterwards. And that's compelling.' Dr Ricardo Almeida-Magana, from UCL, said: 'NeuroSafe offers surgeons a real-time evaluation of the safety of the procedure. 'In standard robotic surgery, surgeons determine whether to choose nerve sparing based on MRI scans, on digital rectal examinations and on biopsy results prior to surgery. 'But whereas those methods can provide guidance, NeuroSafe provides certainty. 'And that opens up the option of nerve-sparing surgery for many more men, without compromising on the chances of controlling the cancer.' Dr Matthew Hobbs, director of research at Prostate Cancer UK, said: 'A major challenge we face is how to cure men but also ensure they can live life to the full afterwards. 'This study is promising and provides evidence that innovative types of surgery can reduce erectile dysfunction in some men — however more research is needed to prove whether NeuroSafe is as effective as traditional techniques at delivering a complete cure. 'We also need to understand exactly which men could benefit from this new technique and, crucially, whether this technique could be delivered at scale across the NHS to make it accessible to men across the UK.'
The Independent
24-03-2025
- Health
- The Independent
Prostate cancer check doubles proportion of men who keep erectile function
A technique to preserve nerves during prostate cancer surgery almost doubles the proportion of men who keep erectile function, according to a new study. Compared to standard surgery, researchers said the new method could dramatically improve men's quality of life. Experts from University College London (UCL) and University College London Hospitals NHS Foundation Trust (UCL H) led the study, which will be presented at the European Association of Urology Congress in Madrid and published in the Lancet Oncology journal. It evaluated a method called NeuroSafe to preserve the nerves running through the prostate's outer layers, which are thought to be responsible for producing erections. During cancer surgery, the prostate is removed while the nerves are left intact. The prostate is then examined closely by a pathologist while the patient is still in surgery. The pathologist slices the area near to the nerves in 5mm strips, which are then quickly frozen and stained so they can be looked at through a microscope. The samples are analysed to see if any cancer cells are present. If there are none, the surgeons know that they can leave the patient's nerves intact in their body. If cancer is present, they know nerves will have to be removed. NeuroSafe happens in real-time during the operation, making it vastly different to traditional methods, where tissue samples are sent off and it takes two or three weeks to get results back. Professor Greg Shaw, trial lead from UCL and consultant urologist at UCLH, said some younger men in particular worry about surgery causing impotence and incontinence. He said: 'Our results show that, by using NeuroSafe, nearly twice as many men don't have to face potentially life-changing loss of erectile function after prostate surgery. 'It is an involved procedure that requires expertise, but it isn't expensive, particularly given the benefits it offers for patients, and most importantly doesn't jeopardise cancer control. 'NeuroSafe wouldn't be appropriate for all patients, as many can safely have nerve-sparing surgery using standard robotic techniques. 'But for younger patients and those who wouldn't normally be seen as eligible for nerve-sparing surgery, it offers them a greater chance to hold onto their quality of life.' Prof Shaw said the technology is not new but 'whereas before there wasn't evidence to support this approach, now we have the data to show that, actually, your outcomes are better'. Some 30% of the men in the study were from Afro Caribbean backgrounds. They tend to be diagnosed at a younger age with prostate cancer than white counterparts. The trial ran at five UK hospitals and included 344 men diagnosed with prostate cancer. Half were randomised to receive NeuroSafe during their operation and half had standard surgery. Twelve months after surgery, 39% of men in the NeuroSafe group had no or mild erectile dysfunction. In those men who had standard surgery, this was 23%. A year after their operation, only 38% of those who had surgery using NeuroSafe had severe erectile dysfunction, compared to 56% of men who had standard surgery. NeuroSafe patients who recovered their urinary control also did so faster than patients who underwent standard surgery. Prof Shaw now hopes more men will be able to access NeuroSafe on the NHS as long as the right pathology support is available. He told the PA news agency: 'Whether it can be rolled out or not depends on, I think, finding a good test that gives a similar result (to the pathologist's work) that's perhaps more easily performed, because it's quite complex. 'But the impetus for the community is you're doubling the chances of a man being potent afterwards. And that's compelling.' Dr Ricardo Almeida-Magana, from UCL, said: 'NeuroSafe offers surgeons a real-time evaluation of the safety of the procedure. 'In standard robotic surgery, surgeons determine whether to choose nerve sparing based on MRI scans, on digital rectal examinations and on biopsy results prior to surgery. 'But whereas those methods can provide guidance, NeuroSafe provides certainty. 'And that opens up the option of nerve-sparing surgery for many more men, without compromising on the chances of controlling the cancer.' Dr Matthew Hobbs, director of research at Prostate Cancer UK, said: 'A major challenge we face is how to cure men but also ensure they can live life to the full afterwards. 'This study is promising and provides evidence that innovative types of surgery can reduce erectile dysfunction in some men — however more research is needed to prove whether NeuroSafe is as effective as traditional techniques at delivering a complete cure. 'We also need to understand exactly which men could benefit from this new technique and, crucially, whether this technique could be delivered at scale across the NHS to make it accessible to men across the UK.'
